← Leaderboards
Courtney Dinardo
University Of Tx Md Anderson Can Ctr
$2,316,391
Attributed
$6,323,170
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,323,170 · 4
By mechanism
R01$5,071,165 · 3
T32$1,252,005 · 1
Top collaborators
- Kapil N. Bhalla10 shared
- Warren Campbell Fiskus6 shared
- Koichi Takahashi4 shared
- Michael Davies2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Kapil N. Bhalla$16,921,043
- Lauren Averett Byers$9,117,683
- Eduardo Vilar Sanchez$16,310,319
- Scott Kopetz$13,199,822
- Yonathan Lissanu$6,037,986
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroComplexResistanceIn VivoHematopoiesisMutationPreclinical EfficacyRepressionMutantTranscription FactorMessenger RnaDysmyelopoietic SyndromesHomoharringtonineDna BindingGraft Vs Host DiseaseHomologous TransplantationLoss Of Function MutationCore-Binding FactorGerm-Line MutationKnock-DownCoupledLibrariesMalignant - DescriptorMediating
Grant awards (12)
Role of targeting ATPases BRG1/BRM in therapy of AML$542,663
R01 · FY2025 · CA
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$496,911
R01 · FY2025 · CA
Research Training in Academic Medical Oncology$649,322
T32 · FY2024 · CA
Novel combination therapy for AML expressing mutant RUNX1$507,478
R01 · FY2024 · CA · contact PI
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$472,065
R01 · FY2024 · CA
Research Training in Academic Medical Oncology$602,683
T32 · FY2023 · CA
Novel combination therapy for AML expressing mutant RUNX1$523,503
R01 · FY2023 · CA · contact PI
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$486,972
R01 · FY2023 · CA
Novel combination therapy for AML expressing mutant RUNX1$523,503
R01 · FY2022 · CA · contact PI
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$486,972
R01 · FY2022 · CA
Novel combination therapy for AML expressing mutant RUNX1$534,187
R01 · FY2021 · CA · contact PI
Biology and novel therapy of AML expressing somatic or germline mutant RUNX1$496,911
R01 · FY2021 · CA